Bacterial loads measured by the xpert MTB/ RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Shenai, Shubhada ^a   Ronacher, Katharina ^b   Malherbe, Stefanus ^b   Stanley, Kim ^b   Kriel, Magdalena ^b   Winter, Jill ^c   Peppard, Thomas ^d   Barry, Charles E ^e   Wang, Jing ^f   Dodd, Lori E ^g   Via, Laura E ^g,h   Barry, Clifton E ^g,h   Walzl, Gerhard ^b   Alland, David ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c Catalysis Foundation for Health   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e BROWN UNIVERSITY   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENOME; BACTERIAL LOAD; BACTERIUM CULTURE; DISEASE ASSOCIATION; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; TUBERCULOSIS RAPID TEST; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; RECEIVER OPERATING CHARACTERISTIC; STANDARDS; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BACTERIAL LOAD; BACTERIOLOGICAL TECHNIQUES; BIOMARKERS; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 84983470396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160062     Document Type: Article

References (25)

1. Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis. The European respiratory journal. 2011; 37(2):376-83. Epub 2010/06/03. doi: 10.1183/09031936.00007410 PMID: 20516049.
2. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(5):560-70. Epub 2010/04/16. PMID: 20392348.
3. Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PloS one. 2015; 10(4):e0125403. doi: 10.1371/journal.pone.0125403 PMID: 25923700; PubMed Central PMCID: PMC4414505.
4. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. The Lancet Respiratory medicine. 2015; 3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3 PMID: 25726085; PubMed Central PMCID: PMC4401426.
5. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. The Lancet infectious diseases. 2010; 10(6):387-94. Epub 2010/06/01. doi: 10.1016/S1473-3099(10)70071-2 PMID: 20510279; PubMed Central PMCID: PMC3046810.
6. Phillips PP, Mendel CM, Burger DA, Crook A, Nunn AJ, Dawson R, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC medicine. 2016; 14(1):19. doi: 10.1186/s12916-016-0565-y PMID: 26847437; PubMed Central PMCID: PMC4743210.
7. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical microbiology reviews. 2011; 24(2):314-50. doi: 10.1128/CMR.00059-10 PMID: 21482728; PubMed Central PMCID: PMC3122496.
8. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, et al. Requirements for high impact diagnostics in the developing world. Nature. 2006; 444 Suppl 1:73-9. doi: 10.1038/nature05448 PMID: 17159896.
9. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS medicine. 2007; 4(3):e120. Epub 2007/03/29. doi: 10.1371/journal.pmed.0040120 PMID: 17388672; PubMed Central PMCID: PMC1831743.
10. Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. The Lancet infectious diseases. 2007; 7(7):481-90. Epub 2007/05/26. doi: 10.1016/S1473-3099(07)70112-3 PMID: 17524807.
11. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 2010; 48(7):2495-501. doi: 10.1128/JCM.00128-10 PMID: 20504986; PubMed Central PMCID: PMCPMC2897495.
12. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. The New England journal of medicine. 2010; 363(11):1005-15. Epub 2010/09/10. doi: 10.1056/NEJMoa0907847 PMID: 20825313; PubMed Central PMCID: PMC2947799.
13. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. American journal of respiratory and critical care medicine. 2011; 184(9):1076-84. Epub 2011/08/13. doi: 10.1164/rccm.201103-0536OC PMID: 21836139; PubMed Central PMCID: PMC3208646.
14. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010; 48(1):229-37. doi: 10.1128/JCM.01463-09 PMID: 19864480; PubMed Central PMCID: PMC2812290.
15. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. The Lancet Respiratory medicine. 2013; 1(6):462-70. Epub 2014/01/17. doi: 10.1016/ S2213-2600(13)70119-X PMID: 24429244.
16. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, et al. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol. 2013; 51(6):1894-8. Epub 2013/04/19. doi: 10.1128/JCM.03290-12 PMID: 23596237; PubMed Central PMCID: PMC3716052.
17. Nicol MP. Xpert MTB/RIF: monitoring response to tuberculosis treatment. The Lancet Respiratory medicine. 2013; 1(6):427-8. Epub 2014/01/17. doi: 10.1016/S2213-2600(13)70133-4 PMID: 24429228.
18. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, Fennelly K, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol. 2010; 48(10):3551-7. Epub 2010/08/20. doi: 10.1128/JCM.01053-10 PMID: 20720033; PubMed Central PMCID: PMC2953088.
19. PT K, GP K. Public health mucobacteriology; a guide for the level III laboratory. Atlanta: Centers for Disease Control, Division of Laboratory Training and Consultation. Atlanta GA, US; 1985.
20. WHO. Definition and Reporting Framework for Tuberculosis-2013 revision. Geneva, Switzerland. World Health Organization, 2013. 2013.
21. McIntosh MW, Pepe MS. Combining several screening tests: Optimality of the risk score. Biometrics. 2002; 58(3):657-64. doi: 10.1111/j.0006-341X.2002.00657.x PMID: WOS:000182975800020.
22. Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest. 1998; 113(2):379-86. Epub 1998/03/14. PMID: 9498955.
23. Chigutsa E, Patel K, Denti P, Visser M, Maartens G, Kirkpatrick CM, et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrobial agents and chemotherapy. 2013; 57 (2):789-95. Epub 2012/11/28. doi: 10.1128/AAC.01876-12 PMID: 23183433; PubMed Central PMCID: PMC3553722.
24. van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PloS one. 2011; 6(12): e28815. doi: 10.1371/journal.pone.0028815 PMID: 22216117; PubMed Central PMCID: PMC3245241.
25. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet infectious diseases. 2010; 10(2):68-9. Epub 2010/02/02. doi: 10.1016/S1473-3099(10)70003-7 PMID: 20113972.